Unblocking Airways: New approaches to preventing mucus plugs
[et_pb_section fb_built="1" _builder_version="4.20.4" _module_preset="default" custom_padding="5px||5px||true|false" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.20.4" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.20.4" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.20.4" _module_preset="default" custom_padding="|13px||9px||" global_colors_info="{}" theme_builder_area="post_content"]
Excess mucus production is a common problem in people with Allergic Bronchopulmonary Aspergillosis (ABPA), and chronic pulmonary aspergillosis (CPA). Mucus is a thick mixture of water, cellular debris, salt, lipids, and proteins. It lines our airways, trapping and removing foreign particles from the lungs. The gel-like thickness of mucus is caused by a family of proteins called mucins. In individuals with asthma, genetic changes to these mucin proteins can thicken the mucus, making it more difficult to clear from the lungs. This thick and dense mucous builds up and can lead to mucus plugs, blocking the airways and causing breathing difficulties, wheezing, coughing, and other respiratory symptoms.
Doctors usually treat these symptoms with inhalable medications such as bronchodilators and corticosteroids to open the airways and reduce inflammation. Mucolytics can also be used to break down mucus plugs, but the only available medication, N-Acetylcysteine (NAC), is not very effective and can cause unwanted side effects. While current treatments can help manage symptoms, there is a need for effective and safe treatments to directly address the issue of mucus plugs.
To address this issue, 3 approaches are being explored:
[/et_pb_text][et_pb_text _builder_version="4.21.0" _module_preset="default" custom_padding="20px|30px|20px|30px|true|true" box_shadow_style="preset1" global_colors_info="{}" theme_builder_area="post_content"]
- Mucolytics to dissolve mucus plugs
Researchers at the University of Colorado are testing new mucolytics such as tris (2-carboxyethyl) phosphine. They gave this mucolytic to a group of asthmatic mice experiencing inflammation and excess mucus production. After treatment, mucus flow improved, and the asthmatic mice could clear mucus just as effectively as the non-asthmatic mice.
However, mucolytics work by breaking the bonds which hold mucins together, and these bonds are found in other proteins in the body. If the bonds are broken in these proteins, it could lead to unwanted side effects. Therefore, further research is needed to discover a drug that will only target the bonds in mucins, reducing the risk of side effects.
[/et_pb_text][et_pb_text _builder_version="4.21.0" _module_preset="default" custom_padding="20px|30px|20px|30px|true|true" box_shadow_style="preset1" global_colors_info="{}" theme_builder_area="post_content"]
2. Clearing crystals
In another approach, Helen Aegerter and her team at the University of Belgium are studying protein crystals which they believe drive mucus overproduction in asthma. These crystals, known as Charcot-Leyden crystals (CLC’s) cause mucus to become thicker, therefore harder to clear from the airways.
To address the crystals directly, the team developed antibodies that attack the proteins in the crystals. They tested the antibodies on mucus samples collected from individuals with asthma. They found that the antibodies effectively dissolved the crystals by attaching themselves to the specific regions of the CLC proteins that hold them together. In addition, the antibodies dampened inflammatory reactions in mice. Based on these findings, the researchers are now working on a drug that could have the same effect in humans. Aegerter believes that this approach could be used to treat a variety of inflammatory diseases that involve excessive mucus production, including sinus inflammation and certain allergic reactions to fungal pathogens (such as ABPA).
[/et_pb_text][et_pb_text _builder_version="4.21.0" _module_preset="default" custom_margin="||30px|||" custom_padding="20px|30px|20px|30px|true|true" box_shadow_style="preset1" global_colors_info="{}" theme_builder_area="post_content"]
- Preventing excess secretion of mucus
In a third approach, pulmonologist Burton Dickey of the University of Texas is working to prevent mucus plugs by reducing the overproduction of mucus. Dickey's team identified a specific gene, Syt2, that is only involved in excessive mucus production and not in normal mucus production. To inhibit excess mucus production, they developed a drug called PEN-SP9-Cy that blocks Syt2's action. This approach is particularly promising as it targets mucus overproduction without interfering with the vital functions of normal mucus. Normal mucus production plays a critical role in protecting and maintaining the health of the respiratory and digestive systems. Although the initial results are promising, further research is necessary to evaluate the efficacy and safety of these drugs in clinical trials.
[/et_pb_text][et_pb_text _builder_version="4.21.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
In summary, mucus plugs present uncomfortable symptoms in ABPA, CPA and asthma. Current treatments focus on symptom management rather than directly addressing reduction or removal of mucus plugs. However, researchers are exploring 3 potential approaches, involving mucolytics, clearing crystals, and preventing excess mucus secretion. Additional research is required to confirm their effectiveness and safety, but approaches have shown promising results and may in future be one way we can prevent mucus plugs.
Further information:
Phlegm, mucus and asthma | Asthma + Lung UK
How to loosen and clear mucus
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Fungal vaccine developments
[et_pb_section fb_built="1" _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.20.2" _module_preset="default" custom_margin="3px|auto|3px|auto|true|false" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
The numbers of people at risk of fungal infections are increasing due to an aging population, increased use of immunosuppressive medications, pre-existing medical conditions, environmental changes, and lifestyle factors. Therefore, there is a growing need for new treatments or preventative options.
Current treatment options for fungal infections often involve the use of antifungal medications, such as azoles, echinocandins, and polyenes. These medications are generally effective in treating fungal infections, but they can have drawbacks. For example, some antifungal drugs can interact with other medications, leading to potentially harmful side effects. Additionally, overuse of antifungal drugs can contribute to the development of antifungal drug resistance, which can make treatment more challenging.
There has been a growing interest in the development of fungal vaccines as an alternative treatment. A fungal vaccine works by stimulating the immune system to produce a specific response against the fungus, which can provide long-term protection against infection. The vaccine could be given to at-risk individuals before exposure to the fungus, preventing infection from occurring in the first place.
[/et_pb_text][et_pb_text _builder_version="4.22.2" _module_preset="624b8eae-e2e0-40f4-a48e-83d57e3006b6" theme_builder_area="post_content" hover_enabled="0" sticky_enabled="0"]
A recent study by researchers from the University of Georgia demonstrated the potential for a pan-fungal vaccine to protect against multiple fungal pathogens, including those that cause aspergillosis, candidiasis, and pneumocystosis. The vaccine, called NXT-2, was designed to stimulate the immune system to recognize and fight against several types of fungi.
The study found that the vaccine was able to induce a strong immune response in mice and additionally protect them from infection with several different fungal pathogens, including Aspergillus fumigatus, which is the main cause of aspergillosis. The vaccine was found to be safe and well-tolerated in the mice, with no adverse effects reported.
This study demonstrates the potential for a pan-fungal vaccine to protect against multiple fungal pathogens. While the study did not specifically address the use of the vaccine in patients with pre-existing aspergillosis infections, the findings suggest that the vaccine has potential to prevent aspergillosis infection in high-risk individuals.
[/et_pb_text][et_pb_text _builder_version="4.22.2" _module_preset="default" theme_builder_area="post_content" hover_enabled="0" sticky_enabled="0"]
In summary, while the development of antifungal vaccines offers a promising potential alternative to the challenges posed by current treatment options for fungal infections, further research is needed to determine the safety and efficacy of the vaccine in humans, including those with aspergillosis, before it can be considered as a treatment option.
Original paper: https://academic.oup.com/pnasnexus/article/1/5/pgac248/6798391?login=false
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Developments in Biologic and Inhaled Antifungal medications for ABPA
[et_pb_section fb_built="1" _builder_version="4.20.2" _module_preset="default" custom_padding="5px||5px||true|false" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.21.0" _module_preset="default" custom_padding="|10px||10px|false|true" global_colors_info="{}" theme_builder_area="post_content"]
ABPA (Allergic Bronchopulmonary Aspergillosis) is a serious allergic disease caused by a fungal infection of the airways. People with ABPA usually have severe asthma and frequent flare-ups that often require long-term use of oral steroids and antibiotics to treat secondary bacterial infections.
The two main treatments for ABPA are antifungal medication and oral steroids. Antifungal medication work by targeting the fungi causing the infection, limiting its growth and spread. This can help reduce the frequency of flare-ups and stabilize the condition but may also cause side effects such as nausea and, more rarely, liver damage. Oral steroids work by reducing inflammation and suppressing the immune system's response to the allergen, which can help control the symptoms of ABPA. However, long-term use can cause significant side effects, including weight gain, mood swings, and adrenal insufficiency.
These side effects can greatly impact quality of life, but both treatments may be necessary to prevent the disease from worsening. Therefore, new or improved treatments are needed.
[/et_pb_text][et_pb_text _builder_version="4.22.2" _module_preset="624b8eae-e2e0-40f4-a48e-83d57e3006b6" global_colors_info="{}" theme_builder_area="post_content"]
Fortunately, there have been recent developments in managing ABPA, and a review by Richard Moss (2023) highlights two promising types of treatment:
- Inhaled antifungal medication treat fungal lung infections by delivering the drug directly to the site of infection. This allows for a higher concentration of the drug to be delivered to the affected area while limiting the exposure of the rest of the body and therefore reduces side effects. For instance, inhaled itraconazole has been shown to reach concentrations high enough to kill or inhibit fungus growth. Further trials will be completed this year (2023) to assess its safety and effectiveness. Although still in development, these drugs offer hope for more effective and better-tolerated treatment options for patients with ABPA.
- Biologic medication is a completely new type of treatment that uses synthetic antibodies to target specific cells or proteins of our immune system instead of using a chemical compound. Omalizumab, a type of biologic, binds to immunoglobulin IgE and deactivates it. IgE is involved in the allergic response our bodies launch against foreign invaders and plays a big role in ABPA symptoms. Deactivation of IgE has been shown to reduce allergic symptoms. In clinical trials omalizumab has been shown to significantly (a) reduced the number of flare-ups compared to pre-treatment, (b) reduced the need for oral steroid use and lowered its necessary dose, (c) increased wean off steroids, (d) improved lung function and (e) improved asthma control. Additionally, other Monoclonal antibodies (Mabs) such as mepolizumab, benralizumab, and dupilumab have shown a reduction in flare-ups, total IgE and a steroid-sparing effect.
[/et_pb_text][et_pb_text _builder_version="4.22.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
According to Moss (2023), these new treatment approaches are highly effective in reducing hospital visits. Biologics seem highly effective, with up to a 90% reduction in flare-ups for ABPA patients and up to 98% efficacy in reducing the amount of oral steroid needed by the patient. If these new treatments continue to work well, it could potentially offer a new, higher quality of life for individuals with ABPA . Overall, these findings are promising, but further research is needed to confirm the effectiveness of these treatments specifically for ABPA.
Original paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861760/
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Spring COVID Booster
COVID-19 levels of infection in the UK are far lower than they have been earlier in the pandemic, even while most people have returned to taking fewer precautions against infection. Increased immunity in the UK population caused by vaccination and infection has likely brought us to this better place.
However levels of immunity are not fixed and much like the common cold it gradually declines in each of us, leaving us open to re-infection within a year. Consequently, we must keep 'topping up' immunity in order to avoid severe symptoms should we be infected. For most of us that are now likely to be a natural process of periodic re-infection until the virus stops circulating so widely.
If you are in a highly vulnerable group it is safest to top-up your immunity without being infected by having a booster vaccination. The Uk government will launch a spring booster campaign shortly to address this need.
Those who will be offered this booster will only be the most at risk, so you may or may not be offered it depending on the opinion of your local hospital doctor or GP. The criteria for the spring booster seem to be more restricted than earlier boosters and will only be offered 6 months after your last booster.
Criteria for the spring campaign are:
- adults aged 75 years and over
- residents in a care home for older adults
- individuals aged 5 years and over who are immunosuppressed (Your doctor will get guidelines to decide this for you)
There will likely be a less restricted booster jab in autumn 2023 too.
NAC CARES team charity run for the Fungal Infection Trust
[et_pb_section fb_built="1" theme_builder_area="post_content" _builder_version="4.19.4" _module_preset="default" custom_padding="4px||4px||true|false"][et_pb_row _builder_version="4.19.4" _module_preset="default" theme_builder_area="post_content" custom_margin="11px|auto|11px|auto|true|false"][et_pb_column _builder_version="4.19.4" _module_preset="default" type="4_4" theme_builder_area="post_content"][et_pb_image src="https://aspergillosis.org/wp-content/uploads/2023/01/lejog.jpg" _builder_version="4.19.4" _module_preset="default" theme_builder_area="post_content" title_text="lejog" hover_enabled="0" sticky_enabled="0" width="49%" module_alignment="center"][/et_pb_image][et_pb_text _builder_version="4.19.4" _module_preset="default" theme_builder_area="post_content" hover_enabled="0" sticky_enabled="0"]
The Fungal Infection Trust (FIT) provides vital support for the work of the CARES team, without which it would be much more difficult to maintain their unique work.
This year, starting on World Aspergillosis Day 2023 (1st Feb) the CARES team is paying back some of that support to FIT.
The Team (Graham/Lauren/Chris/Beth and Seren) have taken on the challenge of getting from one end of the UK to the other with only the power of our legs in 98 days. There are five in the team: two runners, a cyclist and two walkers. We would all normally cover a few km a day so together we think we can cover the 18km A DAY needed to complete this challenge without too many blisters!
With your help we would like to raise £1 a km for the whole journey, so when we are passing your part of the UK (virtually, as we can't get 98 days off work!) please donate.
Keep an eye out for updates on our blog.
Thank You and wish us well!
[/et_pb_text][et_pb_image src="https://aspergillosis.org/wp-content/uploads/2023/01/donate-with-justgiving-1-uai-516x103-1-300x60-1.webp" _builder_version="4.19.4" _module_preset="default" theme_builder_area="post_content" title_text="donate-with-justgiving-1-uai-516x103-1-300x60" hover_enabled="0" sticky_enabled="0" align="center" custom_margin="||28px|||" url="https://www.justgiving.com/campaign/LEJOG-for-Aspergillosis" url_new_window="on"][/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section]
Diagnosis
[et_pb_section fb_built="1" _builder_version="4.19.1" _module_preset="default" custom_margin="|-66px||1px||" custom_padding="0px||3px|0px||" hover_enabled="0" global_colors_info="{}" theme_builder_area="post_content" width="100%" sticky_enabled="0"][et_pb_row _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
Accurate diagnosis has never been straightforward for aspergillosis, but modern tools are being developed rapidly and are now improving the speed and accuracy of diagnosis. A patient presenting at the clinic will first be asked to give a history of the symptoms that they have noticed. Depending on this history a number of tests may be requested from the following list:
- A blood test
- X-rays or CT scan of the chest
- A skin test to measure sensitivity to Aspergillus allergens
- Culture and analysis of a sputum (mucus) sample
- Culture of tissue fluids e.g. lung fluid (called BAL)
- A bronchoscopy – where a flexible tube is passed down into the lungs while under sedation.
- A sample or biopsy of a tissue mass (if present) in a lung cavity
[/et_pb_text][et_pb_divider color="#000000" divider_style="dotted" _builder_version="4.19.1" _module_preset="default" width="80%" module_alignment="center" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_divider][et_pb_text _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
What do the tests show?
Blood tests: Antibodies against Aspergillus proteins can be measured in a patient’s blood and this indicates if the patient may have an Aspergillus infection – this is done using an enzyme-linked immunosorbent assay (ELISA), such as the ImmunoCAP® Specific IgE Blood Test.. A positive result means that antibodies to the fungus have been detected. A positive test result is also a useful marker for later comparisons to assess efficiency of treatment. Occasionally a false positive result may occur which is why a number of different tests are used in diagnosing aspergillosis. Sometimes markers of allergy to Aspergillus are positive in the blood. A test for a particular fungal molecule sometimes found in the blood – called the galactomannan test may also be carried out on a blood sample.
Other tests include blood count, plasma viscosity and C-reactive protein, which may indicate inflammation – such markers usually improve on treatment so a baseline level is helpful. Liver and kidney function tests are important as liver function can be abnormal on antifungal drugs. Also, some aspergillosis patients may have low levels of a substance called mannose binding lectin (MBL) and display abnormal genes for this protein.
A chest X-ray allows visualisation of the inside of the lungs and may identify an abnormality such as any lung cavities – formed as a result of another underlying disease or infection, or if a fungal ball (aspergilloma) is present. A more advanced cross sectional picture of the lungs may be needed, in which case computer tomography (CT) might be necessary. The procedure relies on X-rays to produce a detailed image. You will need to lie still on a narrow table, which slides into the centre of the CT scanner where the X-rays rotate around you. A scan normally takes only a few minutes.
A skin test where a small needle is used to scratch the surface of the skin can be used to detect whether a patient has circulating IgE antibodies specific for Aspergillus. This is a more common test if you have asthma or ABPA. A positive result indicates that the patient is sensitised to Aspergillus. See immune system.
A sample of sputum, other tissue fluids or tissue biopsies may be sent to the laboratory to be cultured, in order to see if it is possible to grow Aspergillus from the sample. Scientists use a special culture plate to grow moulds, and if any does grow they often use a microscope to confirm the type of mould. Another way of detecting Aspergillus is with a sensitive molecular testing method.
A bronchoscopy is a procedure where a flexible tube is passed into the lungs to view the lung and airways – the patient is sedated during the procedure. Samples of the lung tissue or fluids can be biopsied through the bronchoscope for examination in the laboratory by culture and molecular tests, if needed. See more.
Biopsies are small samples of tissue taken from infected areas (e.g. lung, sinus) that are either sliced thinly, stained and examined under a microscope, or are placed on nutrient media that allows any fungus present to grow – the fungus can then be identified.
The results of the above tests are then considered together and if aspergillosis is confirmed a suitable treatment regime will be started.
[/et_pb_text][et_pb_divider color="#000000" divider_style="dotted" _builder_version="4.19.1" _module_preset="default" width="80%" module_alignment="center" custom_margin="7px||11px|||" custom_padding="9px|||||" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_divider][et_pb_text _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
Symptoms:
Symptoms can be widely different depending on the type of aspergillosis that a patient may have. For instance one patient with an aspergilloma may have few symptoms or just a cough, another may cough up large quantities of blood (haemoptysis) and require urgent medical attention The following is a general list of some of the symptoms which aspergillosis patients can experience – but there is a large variation between patients.
- weight loss
- fatigue
- fever
- cough
- coughing blood (haemoptysis)
- breathlessness
A patient with some of these symptoms may not have aspergillosis – in fact it is unlikely, unless the person has a poor immune system (eg. following cancer therapy, organ transplantation). If a person has not responded to several doses of antibiotics and has a weakened immune system then tests for aspergillosis should be considered.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Loneliness and Aspergillosis
[et_pb_section fb_built="1" _builder_version="4.19.1" _module_preset="default" custom_padding="0px||0px|8px||" global_colors_info="{}" theme_builder_area="post_content" custom_margin="|59px||42px||"][et_pb_row _builder_version="4.19.1" _module_preset="default" custom_margin="50px|auto|50px|30px|true|false" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.19.1" _module_preset="default" custom_margin="|-124px||||" custom_padding="|0px||||" global_colors_info="{}" theme_builder_area="post_content"]
Believe it or not, loneliness is as bad for your health as obesity, air pollution or physical inactivity. Some studies put loneliness as equivalent to smoking 15 cigarettes per day.
In a recent poll in our Facebook patient group for people with chronic forms of aspergillosis 40% stated that they were lonely more than once per week and 75% of those stated that they were lonely every day. In total 73% recorded loneliness at least occasionally.
We also asked people who care for aspergillosis patients the same questions and this time 56% stated that they were lonely more than once per week, with 78% lonely at least occasionally.
Give those two poll results, are people lonely because they have a chronic illness that might restrict their socialising, and are they lonely because they look after someone with a chronic illness?
The level of loneliness in the general population in the UK is currently at 45%, so there are clearly more people who are lonely in both groups affected by aspergillosis (73% and 78%). Furthermore, 30% of those people who have chronic aspergillosis in our poll were lonely every day, which compares poorly with national statistics that show the number of people in the general population who are lonely as frequently as every day is only 5%.
Conclusion: There are six times as many people with chronic aspergillosis that are lonely every day compared with the general UK population!
Loneliness is clearly a big problem for people who either have chronic aspergillosis or care for someone with chronic aspergillosis.
What can we do about this?
Firstly, awareness of the problem is a big step forward. Awareness of its far-reaching consequences for our mental and physical health may provide some incentive to take action to try to change things. The campaign to end Loneliness (https://www.campaigntoendloneliness.org/the-facts-on-loneliness/) has found that those affected can be of all ages/genders/able or disabled/chronically ill or not and they aim to inspire everyone to connect and communities to come together to help. Nobody should be without company who wants it.
They also provide a lot of useful hints and tips on how to reduce your loneliness (https://www.campaigntoendloneliness.org/feeling-lonely/ ), how to connect with others a bit better, and reduce your health risks – if nothing else at the moment we all could do with getting together to keep warm! Regardless of why you feel lonely, we can all find a way to make connections no matter how fleeting – they all count.
Here at the National Aspergillosis Centre we hold weekly meetings for all patients both here in the UK and abroad
Zoom meetings are a casual and fun way to chat with fellow aspergillosis travelers and NAC staff (Tuesdays 2-3pm GMT and Thursdays 10 – 11am GMT) in which you can just sit and listen to us all chatting for an hour – all you need is a smartphone/tablet/laptop to join us.
The meetings are private so we do not give instructions on how to join on a public page such as this. For directions on how to get involved join one of the following groups and we will get back to you:
Of course some people are entirely happy on their own
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Doing a disability assessment
[et_pb_section fb_built="1" _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
In order to claim government help for living with a disability you will have to complete a disability assessment. This can be a stressful and demanding experience, so we have gathered some helpful tips from those who have already been through the process.

Keep all of your medical records and letters and make sure you have access to online records and appointments. On the day of the interview, take a copy of all the paperwork with you, so you can refer to it if needed.
Try and keep a diary of all of your symptoms and the effects that they have on your life for a few months before your assessment. Symptoms that may have become routine for you are still severe and need to be mentioned. “Mention every little niggle”.
Speak to Citizens Advice, or the equivalent in other countries, as they are experienced in navigating the large amounts of paperwork and helping you prepare for the interview. Often people are in a difficult emotional state when trying to fill in assessments, and having the support from a third party is a big help.
When asked about your symptoms and how your condition affects your life, think about how you are on your worst days. A ‘good’ day to you almost certainly still involves many wearing symptoms, so make sure you don’t accidentally gloss over anything.
If you’re in the UK, look at subscribing to the Benefits and Work website. They have guides to applying for UK disability benefits, and some of our patients have found their diary templates and wording examples very useful.
Look or ask for tips from others on the Aspergillosis Facebook support group. Also join groups such as The ESA DLA UC & PIP Survival Guide, or the equivalent in other countries.
If you don’t get all you need from your first interview, appeal. Some departments have targets to reach for the first interview, but on appeal you may be more likely to succeed. Even if that’s not the case, you will be better prepared the second time around.
Ensuring aspergillosis is recognised as a severe health condition: As aspergillosis is such a rare condition, those drawing up disability guidelines may not be familiar with the disease. The more people know about aspergillosis, the better! The best way to do this in the UK is to get in touch with your local MP and ask them to check with the Minister of State for Disabled People, Health and Work, to ensure that aspergillosis is included as a long-term, incurable, debilitating condition. Refer your MP to the National Aspergillosis Centre for more information. The more people advocating for aspergillosis patients, the more well-known and understood a condition it will become.
For more information:
Last Updated on June 19, 2019
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Finding an advocate
[et_pb_section fb_built="1" _builder_version="4.19.1" _module_preset="default" width="100%" custom_padding="3px|0px|1px|||" hover_enabled="0" global_colors_info="{}" theme_builder_area="post_content" sticky_enabled="0"][et_pb_row _builder_version="4.19.1" _module_preset="default" custom_padding="22px|2px|22px|2px|true|true" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
If you have concerns with how your condition is being managed, or any questions about aspergillosis and its treatment, you may find yourself needing speak up on behalf of yourself. Most people will be able to do this for themselves, or with help from family and friends, but some may need an independent advocate to help them express their wishes and make informed decisions about their condition. Here are our tips for advocating for yourself, or finding an independent advocate.

Phone your consultant’s secretary or a specialist respiratory nurse from your team (emails sometimes get buried). Use Relay if you struggle with hearing.
Contact the Patient Advice and Liaison Service (PALS) team at your local hospital. PALS will be able to help you answer questions and resolve any concerns you have about your healthcare.
Get in touch with an advocate via your local council or a disability organisation such as VoiceAbility.
Keep pushing until you get what you need.
For more information, see the NHS advice on getting someone to speak up for you
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Managing Chronic Pain
[et_pb_section fb_built="1" _builder_version="4.19.1" _module_preset="default" custom_padding="3px|||2px||" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row column_structure="3_5,2_5" _builder_version="4.21.0" _module_preset="default" custom_margin="45px|auto|5px|auto|false|false" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="3_5" _builder_version="4.21.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.21.0" _module_preset="default" custom_margin="|-51px||||" custom_padding="|41px||||" global_colors_info="{}" theme_builder_area="post_content"]
Chronic pain is common amongst people with chronic respiratory diseases, and also amongst their carers; in fact it is one of the most common reasons for both to visit the doctor. At one time your doctor’s response might have been simple – check that the cause of the pain should clear up with intervention and then prescribe painkiller drugs to help the patient cope with the short period of pain. If the predicted period of pain is not going to be short they might continue to give you painkillers, but after a certain point we know that two things start to happen:
- The painkillers will start giving you side effects, some of which can be serious (eg. depression). The longer you are on the painkillers, and the higher the dose, the worse this can get.
- Some painkillers – especially those used to treat severe pain – start to lose their effectiveness if given over several weeks
[/et_pb_text][/et_pb_column][et_pb_column type="2_5" _builder_version="4.21.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_image src="https://aspergillosis.org/wp-content/uploads/2023/05/managechronpain.jpg" title_text="managechronpain" align="right" _builder_version="4.21.0" _module_preset="default" custom_margin="|||-15px||" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_image][/et_pb_column][/et_pb_row][et_pb_row _builder_version="4.21.0" _module_preset="default" custom_margin="12px|auto|8px|auto|false|false" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.21.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.21.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
Nowadays doctors are more likely to try and encourage patients to remain active, to remain at work and, depending on the source of the pain, might well recommend strengthening exercises (improved muscle tone and strength case help support a painful joint). This also helps the patient to socialise, reduces anxiety and the risk of depression, and can even reduce the pain itself.
But wait! You might ask: Won’t moving a painful joint cause more damage and therefore more pain? If done under medical supervision this is unlikely, and overall the pain usually improves and the dose of painkillers is reduced.
Find out more at: NHS – Managing chronic pain
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version="4.19.1" _module_preset="default" custom_margin="16px|auto|-5px|auto|false|false" custom_padding="31px|4px|40px|4px|false|true" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.21.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
But what about the chest pain often experienced by people with respiratory illness?
Firstly it is important to stress that all chest pain needs to be examined by a doctor as there are several possible causes and some causes need immediate attention e.g. heart attack!
Some chest pain comes from sore bones, muscles and joints so, as we cannot avoid moving our chests during breathing, we tend to reduce movement for a while and take painkillers until the pain is reduced. But, just as written above, your doctor may start to use a variety of approaches to keep your chest moving, build up the muscles to help prevent future pain, and reduce painkiller dose – the same as with any other joint pain.
Find out more at: NHS Chest pain
How can I reduce my dose of painkillers?
There are several techniques that will help you feel more in control of the amount of pain you are in – some are mentioned in the above link, managing chronic pain. Several exploit a little known fact about pain, which most of us will take some convincing of. Our pain is not generated by injury, it is generated by our brains as a defensive mechanism. That suggests that the amount of pain we feel is not inevitable, we might be able to control it a little by using our brains!
Not convinced? Try watching this video recommended by one of our patients, which helped her understand that we can do something to reduce our pain, and possibly even reduce our dose of painkillers.
[/et_pb_text][et_pb_video src="https://www.youtube.com/watch?v=5p6sbi_0lLc" _builder_version="4.19.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_video][/et_pb_column][/et_pb_row][/et_pb_section]
